Clinical Trials on Pulpitis in New Zealand

Total 25 results

Jamia Millia Islamia

Completed

Evaluation of the Effect of Adding Dexamethasone to 2% Lidocaine

Pulpitis - Irreversible

India
Jamia Millia Islamia

Completed

Effect of Intrapulpal Injections on the Post-endodontic Pain

Pulpitis - Irreversible

India
Jamia Millia Islamia

Recruiting

Effect of Alcohol Consumption on the Success Rates

Pulpitis - Irreversible

India
Jamia Millia Islamia

Completed

Use of Tramadol Intraligamentary Injections

Pulpitis

India
Jamia Millia Islamia

Recruiting

Intraligamentary Injections and Post-endodontic Pain

Pulpitis

India
Atlantic Health System
Foundation for Morristown Medical Center

Completed

CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women

Vulvodynia

United States
University of Rochester

Completed

Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

Vulvar Disease

United States
Lumara Health, Inc.

Completed

Vaginal Infection Study

Vaginitis | Vulvovaginitis

United States, Russian Federation, Puerto Rico, India
Viamet

Completed

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Candidiasis, Vulvovaginal

United States
Cidara Therapeutics Inc.

Completed

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Matinas BioPharma Nanotechnologies, Inc.

Completed

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Vulvovaginitis | Candidiasis, Vulvovaginal | Yeast Infection | Yeast Infection Vaginal

United States
Scynexis, Inc.
AWINSA

Recruiting

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

Candida Infection | Vaginal Candidiasis | Vulvovaginal Candidiasis

India
Cidara Therapeutics Inc.

Completed

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
NovaDigm Therapeutics, Inc.

Completed

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Vulvovaginal Candidiasis

United States
Scynexis, Inc.

Completed

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis (DOVE)

Candida Vulvovaginitis

United States
Scynexis, Inc.

Completed

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (Vanish 306)

Candida Vulvovaginitis

United States, Bulgaria
Scynexis, Inc.

Completed

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Vulvovaginal Candidiasis

United States
Mycovia Pharmaceuticals Inc.

Completed

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (VIOLET)

Recurrent Vulvovaginal Candidiasis

United States
Viamet

Completed

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Recurrent Vulvovaginal Candidiasis

United States
MethylGene Inc.

Completed

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Vulvovaginal Candidiasis

United States
Scynexis, Inc.

Completed

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE)

Recurrent Vulvovaginal Candidiasis

United States
GTO Pharmaceutical, LLC

Terminated

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

Female Sexual Dysfunction | Vulvovaginal Atrophy | Vulvodynia | Dyspareunia | Vestibulodynia | Postmenopausal Symptoms | Arousal Disorders, Sexual | Genito-Pelvic Pain/Penetration Disorder | Female Sexual Arousal Disorder | Sexual Pain Disorders

United States
Scynexis, Inc.

Completed

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Candida Vulvovaginitis

United States
Mycovia Pharmaceuticals Inc.

Completed

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections (ultraVIOLET)

Recurrent Vulvovaginal Candidiasis

United States
Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, Germany, Netherlands, South Africa

Clinical Trials on Pulpitis in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations